Read by QxMD icon Read

Gastric Cancer

Tamotsu Sugai, Makoto Eizuka, Noriyuki Arakawa, Mitsumasa Osakabe, Wataru Habano, Yasuko Fujita, Eiichiro Yamamoto, Hiroo Yamano, Masaki Endoh, Takayuki Matsumoto, Hiromu Suzuki
BACKGROUND: We attempted to identify the molecular profiles of gastric intramucosal neoplasia (IMN; low-grade dysplasia, LGD; high-grade dysplasia, HGD; intramucosal cancer, IMC) by assessing somatic copy number alterations (SCNAs) stratified by microsatellite status (microsatellite stable, MSS; microsatellite instable, MSI). Thus, microsatellite status was determined in 84 tumors with MSS status and 16 tumors with MSI status. METHODS: One hundred differentiated type IMNs were examined using SCNAs...
February 21, 2018: Gastric Cancer
(no author information available yet)
No abstract text is available yet for this article.
February 21, 2018: Gastric Cancer
Hu Yue, Liu Shan, Lv Bin
BACKGROUND: Despite extensive research on the criteria for the assessment of gastric cancer risk using the Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastritis/Intestinal-Metaplasia Assessment (OLGIM) systems, no comprehensive overview or systematic summary on their use is currently available. AIM: To perform a systematic review and meta-analysis to assess the efficacy of the OLGA and OLGIM staging systems in evaluating gastric cancer risk...
February 19, 2018: Gastric Cancer
Ting-Ting Zhao, Hao Xu, Hui-Mian Xu, Zhen-Ning Wang, Ying-Ying Xu, Yong-Xi Song, Song-Cheng Yin, Xing-Yu Liu, Zhi-Feng Miao
BACKGROUND: Advanced gastric cancer (AGC) is a severe malignant tumor associated with high mortality. Targeted therapy is an important approach for improving the therapeutic effects of AGC treatment. This study evaluates the efficacy and safety of targeted agents for AGC patients. METHODS: PubMed, EmBase, and the Cochrane Library were searched for double-blind randomized controlled trials (RCTs) of AGC treatments published prior to July 2017. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and severe adverse effects (AEs) were evaluated to determine the efficacy and safety of targeted agents...
February 17, 2018: Gastric Cancer
Minkyo Song, M Constanza Camargo, Stephanie J Weinstein, Ana F Best, Satu Männistö, Demetrius Albanes, Charles S Rabkin
BACKGROUND: Family history may inform risks of gastric cancer and preneoplastic lesions. METHODS: We examined associations with history of cancer in first-degree relatives for 307 incident gastric cancer cases among 20,720 male smokers in a prospective study in Finland. Cox regression was used to calculate gastric cancer hazard ratios (HR) and 95% confidence intervals (95% CI). Logistic regression was used to estimate odds ratios (OR) and 95% CIs for low serum pepsinogen, a marker of gastric atrophy...
February 17, 2018: Gastric Cancer
Satoshi Kamiya, Naoki Hiki, Koshi Kumagai, Michitaka Honda, Souya Nunobe, Manabu Ohashi, Takeshi Sano, Toshiharu Yamaguchi
BACKGROUND: Early identification of patients at risk of postoperative pancreatic fistula (POPF) allows appropriate management after gastrectomy. Although some reports have suggested a correlation between POPF and the concentration of amylase in drained abdominal fluid (D-AMY), this has not been proven to impact sufficiently on clinical decision-making. A sustained high level of D-AMY is often assumed to be due to unsatisfactory drainage or excessive pancreatic leakage. We assessed the clinical utility of measuring D-AMY on postoperative day (POD) 1 and POD3 for prediction of POPF...
February 13, 2018: Gastric Cancer
Masahiro Maeda, Satoshi Yamashita, Taichi Shimazu, Naoko Iida, Hideyuki Takeshima, Takeshi Nakajima, Ichiro Oda, Sohachi Nanjo, Chika Kusano, Akiko Mori, Hiroshi Moro, Harumi Yamada, Shoichiro Tsugane, Toshiro Sugiyama, Yoshiharu Sakai, Toshikazu Ushijima
BACKGROUND: The risk stratification of healthy individuals after Helicobacter pylori eradication is an urgent issue. The assessment of aberrant DNA methylation accumulated in gastric tissues with normal appearance, which can reflect overall epigenomic damage, is a promising strategy. We aimed to establish novel epigenetic cancer risk markers for H. pylori-eradicated individuals. METHODS: Gastric mucosa was collected from eight healthy volunteers without H. pylori infection (G1), 75 healthy individuals with gastric atrophy (G2), and 94 gastric cancer patients (G3) after H...
February 9, 2018: Gastric Cancer
Yasuhiro Kodera, Kazuhiro Yoshida, Hiraku Kumamaru, Yoshihiro Kakeji, Naoki Hiki, Tsuyoshi Etoh, Michitaka Honda, Hiroaki Miyata, Yuichi Yamashita, Yasuyuki Seto, Seigo Kitano, Hiroyuki Konno
BACKGROUND: Although laparoscopic total gastrectomy (LTG) is considered a technically demanding procedure with safety issues, it has been performed in several hospitals in Japan. Data from a nationwide web-based data entry system for surgical procedures (NCD) that started enrollment in 2011 are now available for analysis. METHODS: A retrospective cohort study was conducted using data from 32,144 patients who underwent total gastrectomy and were registered in the NCD database between January 2012 and December 2013...
February 9, 2018: Gastric Cancer
Minkyu Jung, Min-Hee Ryu, Do Youn Oh, Myounghee Kang, Dae Young Zang, In Gyu Hwang, Keun-Wook Lee, Ki Hyang Kim, Byoung Yong Shim, Eun Kee Song, Sun Jin Sym, Hye Sook Han, Young Lee Park, Jin Soo Kim, Hyun Woo Lee, Moon Hee Lee, Dong-Hoe Koo, Hong Suk Song, Namsu Lee, Sung Hyun Yang, Dae Ro Choi, Young Seon Hong, Kyoung Eun Lee, Chi Hoon Maeng, Jin Ho Baek, Samyong Kim, Yeul Hong Kim, Sun Young Rha, Jae Yong Cho, Yoon-Koo Kang
BACKGROUND: Ramucirumab improves survival in gastric cancer patients. The efficacy and safety of ramucirumab outside of a clinical trial were evaluated using an expanded access program (EAP). METHODS: Advanced gastric cancer patients treated with ramucirumab in combination with paclitaxel or with ramucirumab monotherapy in a Korean EAP were evaluated. Baseline characteristics were assessed for progression-free survival (PFS) and overall survival (OS), and adverse events were evaluated according to the treatment regimen...
February 9, 2018: Gastric Cancer
Fausto Rosa, Giuseppe Quero, Claudio Fiorillo, Massimiliano Bissolati, Chiara Cipollari, Stefano Rausei, Damiano Chiari, Laura Ruspi, Giovanni de Manzoni, Guido Costamagna, Giovanni Battista Doglietto, Sergio Alfieri
BACKGROUND: The aim of this study is to compare surgical outcomes including postoperative complications and prognosis between total gastrectomy (TG) and proximal gastrectomy (PG) for proximal gastric cancer (GC). Propensity-score-matching analysis was performed to overcome patient selection bias between the two surgical techniques. METHODS: Among 457 patients who were diagnosed with GC between January 1990 and December 2010 from four Italian institutions, 91 underwent PG and 366 underwent TG...
February 8, 2018: Gastric Cancer
Meng Xue, Lu-Yi Chen, Wei-Jia Wang, Ting-Ting Su, Liu-Hong Shi, Lan Wang, Wen Zhang, Jian-Min Si, Liang-Jing Wang, Shu-Jie Chen
BACKGROUND: Long non-coding RNAs (LncRNAs) exert their functions mainly by binding to their corresponding proteins. Runt-related transcription factor 3 (Runx3) is an important transcription factor that functions as a tumor suppressor in gastric cancer. Whether there is an interplay between LncRNAs and Runx3 remains unclear. METHODS: RPISeq was applied to screen the LncRNAs that potentially bind to Runx3. The interaction between LncRNA HOX antisense intergenic RNA (HOTAIR) and Runx3 was validated by RNA Immunoprecipitation and RNA pull-down assays...
February 7, 2018: Gastric Cancer
A Scott Paulson, Lisa M Hess, Astra M Liepa, Zhanglin Lin Cui, Kathleen M Aguilar, Jamyia Clark, William Schelman
BACKGROUND: Limited real-world research has investigated ramucirumab for the treatment of patients with gastric or gastroesophageal junction (GEJ) cancer. This study was designed to describe ramucirumab monotherapy or combination therapy use in a community oncology practice setting. METHODS: This was a retrospective observational cohort study to describe the treatment of adult patients with gastric or GEJ cancer who initiated ramucirumab treatment between 4/21/14 and 6/30/16 within the US Oncology Network...
February 3, 2018: Gastric Cancer
Thomas Abrams, Lisa M Hess, Yajun Emily Zhu, William Schelman, Astra M Liepa, Charles Fuchs
BACKGROUND: Patients with metastatic gastric cancer have a poor prognosis (5-year survival of less than 10%). This study was designed to describe the treatment patterns of patients with gastric cancer and to understand the factors associated with treatment choices to inform evidence-based care. METHODS: A retrospective observational study was conducted using two real-world databases to describe treatment trends and to quantify variability in treatment patterns of patients diagnosed with advanced/metastatic gastric cancer between 1/1/2007 and 9/30/2014 in the U...
February 1, 2018: Gastric Cancer
Qi-Yue Chen, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jian-Xian Lin, Jun Lu, Long-Long Cao, Mi Lin, Ru-Hong Tu, Ze-Ning Huang, Ju-Li Lin, Chang-Ming Huang
BACKGROUND: The oncologic outcome of laparoscopic radical gastrectomy (LG) with open radical gastrectomy (OG) for gastric cancer with preoperative enlarged lymph nodes (LNs) remains ambiguous. METHODS: The long-term outcomes of LG (n = 855) versus OG (n = 154) in gastric adenocarcinoma patients were analyzed retrospectively. Patients were stratified according to enlarged (> 10 mm) and small (≤ 10 mm) LNs (ELN and SLN) based on the long-axis diameter of the LNs...
January 30, 2018: Gastric Cancer
Emil Ter Veer, Jessy Joy van Kleef, Mirjam A G Sprangers, Nadia Haj Mohammad, Martijn G H van Oijen, Hanneke W M van Laarhoven
BACKGROUND: Health-related quality of life (HRQoL) assessments are increasingly incorporated into oncological randomized controlled trials (RCTs). The quality of HRQoL reporting in RCTs concerning palliative systemic treatment for advanced esophagogastric cancer is currently unknown. Therefore, we conducted a systematic review to investigate the quality of HRQoL reporting over time. METHODS: PubMed, CENTRAL and EMBASE were searched for RCTs concerning systemic treatment for advanced esophagogastric cancer up to February 2017...
January 29, 2018: Gastric Cancer
Hyeong Su Kim, Min-Hee Ryu, Dae Young Zang, Sook Ryun Park, Boram Han, Won Ki Kang, Sun Young Rha, Minkyu Jung, Jin-Soo Kim, Byung Woog Kang, Kyung-Hee Lee, Sang-Young Rho, Jung Han Kim, Kab Choong Kim, Ji Woong Cho, Dae Ro Choi, Hyun Lim, Ho Suk Kang, Jae Seung Soh, Min-Jeong Kim, Jinwon Seo, Yoon-Koo Kang
BACKGROUND: Doublet chemotherapy of platinum and 5-fluorouracil is a standard first-line treatment for patients with unresectable gastric cancer. Although the addition of taxane or irinotecan to this regimen has yielded promising efficacy, its use has been limited due to severe toxicities. To overcome this limitation, we evaluated the efficacy and safety of the combination of irinotecan, oxaliplatin, and S-1 (OIS) for the treatment of advanced gastric cancer. METHODS: Chemotherapy-naïve patients with pathologically proven advanced gastric adenocarcinoma were assessed for eligibility...
January 25, 2018: Gastric Cancer
Zhining Liu, Weidong Ren, Jintao Guo, Ying Zhao, Siyu Sun, Yuhong Li, Zhijun Liu
OBJECTIVE: Transabdominal ultrasound after oral administration of an echoic cellulose-based gastric ultrasound contrast agent (TUS-OCCA) has recently been suggested as a valuable mass-screening tool for gastric cancer. The aim of this study was to propose a producible stomach ultrasound reporting and data system (Su-RADS) using TUS-OCCA for gastric cancer screening. PATIENTS: The study includes information of 2738 patients who underwent both gastroscopy and TUS-OCCA examinations recorded in software system...
January 25, 2018: Gastric Cancer
Etsuro Bando, Rie Makuuchi, Tomoyuki Irino, Yutaka Tanizawa, Taiichi Kawamura, Masanori Terashima
BACKGROUND: In the 8th edition of the tumor-node-metastasis (TNM) classification, the gastric cancer staging system includes two classifications: the clinical stage (cStage) and the postoperative pathologic stage. However, the correlation between the new cStage and overall survival has not been studied. Moreover, clinical N (cN) grade analysis is not included in the new clinical staging system. This study validated the prognostic value of cStage in the 8th edition of the TNM classification and the significance of N classification for pretreatment staging in gastric cancer...
January 22, 2018: Gastric Cancer
Noboru Kawata, Hiroyuki Ono, Kohei Takizawa, Naomi Kakushima, Masaki Tanaka, Kimihiro Igarashi, Masao Yoshida, Yoshihiro Kishida, Tomohiro Iwai, Sayo Ito, Kenichiro Imai, Kinichi Hotta, Hirotoshi Ishiwatari, Hiroyuki Matsubayashi
BACKGROUND: A novel method for the prevention of bleeding after gastric endoscopic submucosal dissection (ESD) is necessary, as the numbers of patients taking antithrombotic agents have increased. This study aimed to assess the efficacy and safety of the covering method using polyglycolic acid (PGA) sheets and fibrin glue for ESD-induced ulcer in preventing post-ESD bleeding in patients under continued antithrombotic agents. METHODS: One hundred five consecutive gastric tumors among 84 patients who were treated by ESD under continued antithrombotic agents between April 2014 and September 2015 were enrolled in this study...
January 22, 2018: Gastric Cancer
Akitaka Makiyama, Kenji Kunieda, Masaaki Noguchi, Takeshi Kajiwara, Takao Tamura, Koji Takeda, Junko Sugiyama, Keiko Minashi, Toshikazu Moriwaki, Naotoshi Sugimoto, Michitaka Nagase, Yuji Negoro, Takashi Tsuda, Hideki Shimodaira, Naohiro Okano, Akihito Tsuji, Daisuke Sakai, Kazuhiro Yanagihara, Shinya Ueda, Shingo Tamura, Satoshi Otsu, Takuya Honda, Yuzo Matsushita, Tatsuya Okuno, Tomomi Kashiwada, Akira Nozaki, Masahide Ebi, Hiroyuki Okuda, Mototsugu Shimokawa, Shuichi Hironaka, Ichinosuke Hyodo, Eishi Baba, Narikazu Boku, Kei Muro, Taito Esaki
BACKGROUND: Fluoropyrimidine and platinum combination is the standard treatment for advanced or recurrent gastric cancer (AGC). However, fluoropyrimidine monotherapy is commonly used for elderly patients with AGC because of its good tolerability. METHODS: In this multicenter retrospective study, we collected clinical data of AGC patients aged 70 years or older, treated with S-1 alone or S-1 plus cisplatin (SP) as the first-line treatment between January 2009 and December 2011...
January 20, 2018: Gastric Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"